Company Description
Akari Therapeutics, Plc, an oncology company, develops next-generation antibody-drug conjugates (ADC) for cancer-killing toxins.
Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing.
The company’s lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, colon, and prostate.
Its payloads include PH5, which inhibits DNA mismatch repair (MMR) and DNA damage response (DDR) to generate neoepitopes, and PH6, which inhibits DNA transcription in cancer cells and co-opted immune cells.
The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers.
Akari Therapeutics, Plc is headquartered in Boston, Massachusetts.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 9 |
| CEO | Abizer Gaslightwala |
Contact Details
Address: 22 Boston Wharf Road, Floor 7 Boston, Massachusetts 02210 United States | |
| Phone | 929 274 7510 |
| Website | akaritx.com |
Stock Details
| Ticker Symbol | AKTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001541157 |
| CUSIP Number | 00972G108 |
| ISIN Number | US00972G2075 |
| Employer ID | 98-1034922 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Abizer Gaslightwala | Chief Executive Officer, President and Director |
| Dr. Torsten Hombeck Ph.D. | Chief Financial Officer |
| Dr. Satyajit Mitra Ph.D. | Executive Director and Head of Oncology |
| Mark F. Kubik M.B.A. | Head of Business Development - Oncology |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 29, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Jul 29, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Jul 1, 2025 | 8-K | Current Report |
| Jun 6, 2025 | ARS | Filing |
| Jun 6, 2025 | DEF 14A | Other definitive proxy statements |
| May 23, 2025 | PRE 14A | Other preliminary proxy statements |
| May 15, 2025 | 8-K | Current Report |
| May 14, 2025 | EFFECT | Notice of Effectiveness |
| May 14, 2025 | 10-Q | Quarterly Report |
| May 14, 2025 | 424B3 | Prospectus |